FDA Approves Apellis’ EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment

First C3 inhibitor for IC-MPGN and C3G

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.